FDA approves Pfizer's rheumatoid arthritis treatment

Share this article:
FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Share this article:

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.